Skip to Content
Merck
All Photos(1)

Key Documents

SAB2501559

Sigma-Aldrich

Anti-BIRC3 antibody produced in goat

affinity isolated antibody, buffered aqueous solution

Synonym(s):

Anti-AIP1, Anti-API2, Anti-CIAP2, Baculoviral IAP repeat-containing 3

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

goat

Quality Level

100

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

species reactivity

human

technique(s)

indirect ELISA: suitable
western blot: suitable

UniProt accession no.

Q13489

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... BIRC3(330)

Immunogen

Peptide with sequence SVNNLEATSQP, from the internal region of the protein sequence according to NP_001156.1

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Physical form

Supplied at 0.5 mg/mL in 20mM Tris (pH 7.3) and 150mM NaCl with 0.02% sodium azide and 0.5% bovine serum albumin.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jeffrey R Infante et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(28), 3103-3110 (2014-08-13)
LCL161 antagonizes the function of inhibitor of apoptosis proteins (IAPs), thereby promoting cancer cell death. This first-in-human dose-escalation study assessed the maximum-tolerated dose (MTD), safety, pharmacokinetics, and pharmacodynamics of LCL161 in patients with advanced solid tumors. A second part of
Piotr Smolewski et al.
International journal of oncology, 45(1), 419-425 (2014-05-03)
Although major advancements in antitumor treatment have been observed, several B cell-derived malignancies still remain incurable. A promising approach that involves targeting RNA either by the use of specific antisense oligonucleotides or cytostatic/cytotoxic ribonucleases (RNases) is being promoted. Two amphibian

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service